Overview
NAD+ (nicotinamide adenine dinucleotide), NMN (nicotinamide mononucleotide), and NR (nicotinamide riboside) represent three interconnected nodes of the NAD+ biosynthesis pathway — each studied for their potential to restore declining NAD+ levels associated with aging, metabolic dysfunction, and cellular stress. Understanding the relationship between these three compounds is essential for researchers studying sirtuin activation, mitochondrial biogenesis, DNA repair, and longevity biology.
The NAD+ Biosynthesis Pathway
NAD+ cannot be directly supplemented effectively in most oral research contexts due to poor membrane permeability and rapid degradation. Cells rely on precursors converted intracellularly: Tryptophan → NR → NMN → NAD+. NR is converted to NMN by NR kinases (NRK1/2), then NMN is converted to NAD+ by NMNAT enzymes. Tissue-specific expression of these enzymes means that different precursors may be more effective in different organ systems — a key variable in comparative research designs.
NMN in Research
NMN has been extensively studied in David Sinclair’s lab (Harvard) and Shin-ichiro Imai’s lab (Washington University). Animal studies show NMN reverses age-related physiological decline, restores NAD+ levels in multiple tissues, improves insulin sensitivity, and enhances mitochondrial function. Human trials confirm oral NMN raises NAD+ in skeletal muscle in older adults. Research is also exploring NMN in the context of GLP-1-driven weight loss, where NAD+ repletion may help preserve muscle mass.
NR in Research
NR was among the first NAD+ precursors to reach human clinical trials. Multiple studies confirm NR raises blood NAD+ dose-dependently. Research has explored NR in cardiovascular disease, Parkinson’s disease, and metabolic syndrome. NR requires conversion to NMN before NAD+ synthesis — one additional enzymatic step that may represent a rate-limiting factor in some tissues, though head-to-head human trials show broadly similar NAD+-raising efficacy between NMN and NR.
Direct NAD+ in Research
Intravenous NAD+ bypasses oral bioavailability issues and is actively studied in addiction medicine, neurodegeneration, and metabolic research. Intranasal administration is being explored for CNS delivery. For most preclinical oral supplementation protocols, NMN or NR is preferred over direct NAD+ administration.
Research Use Only
NAD+, NMN, and NR are available from FenaLife for laboratory research use only. Not for human or veterinary use.
🔬 Research Compounds Referenced: NAD+ 500mg